Key Points
- Insider sale: Rapport Therapeutics director David Bredt sold 8,500 shares on Feb. 17 at an average price of $29.02 for $246,670, lowering his stake to 387,075 shares (a 2.15% decrease) after a string of recent sales (8,500 on Jan. 15, 6,567 on Dec. 31, and 8,500 on Dec. 15).
- Market and analyst context: RAPP shares traded down to $29.49 (down 1.7%), with a $1.41 billion market cap and a 1‑year range of $6.43–$42.27, while analysts are mostly bullish—consensus rating "Moderate Buy" with a $50.80 average price target.
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider David Bredt sold 8,500 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $29.02, for a total transaction of $246,670.00. Following the completion of the transaction, the insider directly owned 387,075 shares of the company's stock, valued at $11,232,916.50. The trade was a 2.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
David Bredt also recently made the following trade(s):
- On Thursday, January 15th, David Bredt sold 8,500 shares of Rapport Therapeutics stock. The stock was sold at an average price of $26.84, for a total transaction of $228,140.00.
- On Wednesday, December 31st, David Bredt sold 6,567 shares of Rapport Therapeutics stock. The shares were sold at an average price of $30.05, for a total transaction of $197,338.35.
- On Monday, December 15th, David Bredt sold 8,500 shares of Rapport Therapeutics stock. The stock was sold at an average price of $30.02, for a total transaction of $255,170.00.
Rapport Therapeutics Trading Down 1.7%
Shares of NASDAQ:RAPP traded down $0.50 on Friday, hitting $29.49. 104,116 shares of the company were exchanged, compared to its average volume of 331,002. The firm has a market capitalization of $1.41 billion, a P/E ratio of -10.89 and a beta of 1.63. Rapport Therapeutics, Inc. has a 1-year low of $6.43 and a 1-year high of $42.27. The stock's 50 day moving average price is $28.34 and its 200 day moving average price is $25.36.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. Meeder Asset Management Inc. acquired a new position in Rapport Therapeutics in the fourth quarter valued at approximately $37,000. Russell Investments Group Ltd. acquired a new stake in shares of Rapport Therapeutics during the 3rd quarter worth approximately $43,000. Strs Ohio increased its holdings in shares of Rapport Therapeutics by 23.5% during the 3rd quarter. Strs Ohio now owns 2,100 shares of the company's stock valued at $62,000 after purchasing an additional 400 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Rapport Therapeutics by 64.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company's stock valued at $70,000 after purchasing an additional 905 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Rapport Therapeutics in the 3rd quarter valued at $143,000.
Analysts Set New Price Targets
A number of research analysts have recently weighed in on RAPP shares. Citigroup reissued a "market outperform" rating on shares of Rapport Therapeutics in a report on Thursday, January 8th. BTIG Research reiterated a "buy" rating and issued a $47.00 target price on shares of Rapport Therapeutics in a research report on Monday, December 8th. HC Wainwright raised their price target on shares of Rapport Therapeutics from $34.00 to $40.00 and gave the stock a "buy" rating in a research report on Tuesday, December 9th. Wall Street Zen cut shares of Rapport Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, February 7th. Finally, Wells Fargo & Company began coverage on shares of Rapport Therapeutics in a research note on Monday, February 2nd. They issued an "overweight" rating and a $43.00 price objective on the stock. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Rapport Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $50.80.
Get Our Latest Stock Report on Rapport Therapeutics
Rapport Therapeutics Company Profile
(
Get Free Report)
Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.
Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
